U.S. patent application number 15/296368 was filed with the patent office on 2017-02-09 for multi-layered orally disintegrating tablet and the manufacture thereof.
The applicant listed for this patent is Johnson & Johnson Consumer Inc.. Invention is credited to Frank J. Bunick, Leo B. Kriksunov, Joseph R. Luber, Harry S. Sowden, Christopher E. Szymczak.
Application Number | 20170035656 15/296368 |
Document ID | / |
Family ID | 45352789 |
Filed Date | 2017-02-09 |
United States Patent
Application |
20170035656 |
Kind Code |
A1 |
Luber; Joseph R. ; et
al. |
February 9, 2017 |
MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE
THEREOF
Abstract
The present invention features a tablet containing a first layer
and a second layer, wherein: (i) the first layer includes a
pharmaceutically active agent and the composition of the first
layer is different from the composition of the second layer; (ii)
the tablet has a density less than about 0.8 g/cc; and (iii) the
tablet disintegrates in the mouth when placed on the tongue in less
than about 30 seconds.
Inventors: |
Luber; Joseph R.;
(Quakertown, PA) ; Bunick; Frank J.; (Randoph,
NJ) ; Sowden; Harry S.; (Glenside, PA) ;
Kriksunov; Leo B.; (Ithaca, NY) ; Szymczak;
Christopher E.; (Marlton, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Johnson & Johnson Consumer Inc. |
Skillman |
NJ |
US |
|
|
Family ID: |
45352789 |
Appl. No.: |
15/296368 |
Filed: |
October 18, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13052316 |
Mar 21, 2011 |
|
|
|
15296368 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
B30B 15/34 20130101;
A61K 9/146 20130101; B29C 43/146 20130101; A61P 29/00 20180101;
B30B 11/10 20130101; A61K 9/145 20130101; A61K 31/4545 20130101;
A61K 9/2031 20130101; A61K 9/2018 20130101; A61K 9/2086 20130101;
A61K 9/2095 20130101; A61K 31/138 20130101; B30B 11/085 20130101;
A61K 31/167 20130101; A61K 9/0056 20130101; B29C 43/006 20130101;
A61K 9/205 20130101; A61P 37/08 20180101; A61K 9/2036 20130101;
B30B 11/027 20130101; B29C 2043/3628 20130101; A61J 3/10
20130101 |
International
Class: |
A61J 3/10 20060101
A61J003/10; A61K 9/20 20060101 A61K009/20; B29C 43/14 20060101
B29C043/14; A61K 31/138 20060101 A61K031/138; A61K 31/167 20060101
A61K031/167; A61K 9/00 20060101 A61K009/00; A61K 31/4545 20060101
A61K031/4545 |
Claims
1. A process for making a tablet comprising a first layer and a
second layer, said method comprising: adding a first powder blend
to a die platen, wherein said first powder blend comprises a
pharmaceutically active agent and a binder; adding a second powder
blend to said die platen, wherein said second powder blend
comprises a binder and wherein the composition of said second
powder blend is different from the composition of said first powder
blend; tamping said first powder blend and second powder blend in
said die platen to form a tamped tablet shape; and applying energy
to said tamped tablet shape for a sufficient period of time to
activate said binders within said tablet shape to fuse said tablet
shape into said tablet such that said tablet has a density less
than about 0.8 g/cc and said tablet disintegrates in the mouth when
placed on the tongue in less than about 30 seconds.
2. The process of claim 1, wherein said binder within said first
powder blend and said binder within said second powder blend are
meltable materials having a melting point of from about 30.degree.
C. to about 140.degree. C. and said tablet shape is exposed to said
energy for a sufficient period of time to melt or soften said
binders.
3. The process of claim 1, wherein said binder within said first
powder blend is a RF-meltable binder, and said tablet shape is
exposed to RF energy for a sufficient period of time to melt or
soften said RF-meltable binder.
4. The process of claim 1, wherein said first powder blend
comprises a RF-heatable material, and said tablet shape is exposed
to RF energy for a sufficient period of time to heat said
RF-heatable material such that said RF-heatable material melts or
softens said binder within said first powder blend.
5. The process of claim 1, wherein said binder within said first
powder blend and said binder within said second powder blend are
water-activating binding materials, said first powder blend and
said second powder blend further comprise water-containing
materials, and said tablet shape is exposed to said energy for a
sufficient period of time to heat the water-containing materials
above their dehydration temperature.
6. The process of claim 1, wherein said first powder blend
comprises particles comprising said first pharmaceutically active
agent wherein said particles are coated with said binder.
7. The process of claim 1, wherein said process further comprises
tamping said first powder blend prior to adding said second powder
blend to said die platen.
8. The process of claim 1, wherein the surface of said tablet is
further exposed to infrared energy wherein the majority of the
wavelength of said infrared energy from about 0.5 to about 5
micrometers.
9. The process of claim 1 wherein said tamping step comprises
tamping at a pressure of less than about 1000 pounds per square
inch.
10. The process of claim 1 wherein said tamping of said first
powder blend is done at a pressure of less than about 1000 pounds
per square inch prior to adding said second powder blend.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This is a divisional application which claims the benefits
of U.S. patent application Ser. No. 13/052,316, filed Mar. 21,
2011, U.S. patent application Ser. No. 12/887,552, filed Sep. 22,
2010, U.S. patent application Ser. No. 12/887,544, filed Sep. 22,
2010 (now U.S. Pat. No. 8,871,263), U.S. Provisional Application
Ser. No. 61/358,167, filed Jun. 24, 2010, U.S. Provisional
Application Ser. No. 61/314,629, filed Mar. 17, 2010, U.S.
Provisional Application Ser. No. 61/255,582, filed Oct. 28, 2009,
U.S. Provisional Application Ser. No. 61/245,315, filed Sep. 24,
2009. The complete disclosures of the aforementioned related U.S.
patent applications are hereby incorporated herein by reference for
all purposes.
BACKGROUND OF THE INVENTION
[0002] Pharmaceuticals intended for oral administration are
typically provided in tablet form. Tablets are swallowed whole,
chewed in the mouth, or disintegrated in the oral cavity. Soft
tablets that either are chewed or dissolve in the mouth are often
employed in the administration of pharmaceuticals where it is
impractical to provide a tablet for swallowing whole. With chewable
tablets, the act of chewing helps to break up the tablet particles
as the tablet disintegrates and may increase the rate of absorption
by the digestive tract. Soft tablets are also advantageous where it
is desirable to make a pharmaceutically active agent available
topically in the mouth or throat for both local effects and/or
systemic absorption. Soft tablets are also utilized to improve drug
administration in pediatric and geriatric patients. Soft tablets
designed to disintegrate in the mouth prior to swallowing are
particularly useful for improving compliance of pediatric
patients.
[0003] Generally, soft tablets are made by compaction of a blend of
powdered ingredients and typically include a pharmaceutically
active agent, flavoring, and/or binders. The powder blend is
typically fed into the cavity of a die of a tablet press and a
tablet is formed by applying pressure. Hardness of the resulting
tablet is a direct function of the compaction pressure employed and
the compatibility of the ingredients in the formulation. A softer
tablet, having an easier bite-through, may be prepared by employing
reduced compaction pressures. The resulting tablet is softer, but
also more fragile, brittle, and easily chipped and
disadvantageously can involve complex and costly processing steps.
Examples of soft tablets designed to disintegrate in the mouth
without chewing are disclosed in U.S. Pat. Nos. 5,464,632,
5,223,264, 5,178,878, 6,589,554, and 6,224,905.
[0004] There is a need for aesthetically pleasing chewable and
orally disintegrating tablets that utilizes compression-based
tableting machines typically used to produce high density, hard
swallowable tablets. When used at low compression forces, these
machines typically produce highly friable tablets, which are not
sufficiently stable during packaging, shipping, and storage. The
present invention relates to the discovery of a process for making
tablets, such as chewable or orally disintegrating tablets, using
radiofrequency energy ("RF energy") that can utilize high speed
tableting machines.
SUMMARY OF THE INVENTION
[0005] In one aspect, the present invention features a process for
making a tablet by compacting a powder blend in a die platen to
form a tablet shape, wherein the powder blend includes a
pharmaceutically active agent and a meltable binder, and applying
radiofrequency energy to the tablet shape for a sufficient period
of time to soften or melt the binder within the tablet shape to
form the tablet. In one embodiment, the resulting tablet is an
orally disintegrating tablet ("ODT").
[0006] In one aspect, the present invention features a tablet
containing a first layer and a second layer, wherein: (i) the first
layer includes a pharmaceutically active agent and the composition
of the first layer is different from the composition of the second
layer; (ii) the tablet has a density less than about 0.8 g/cc; and
(iii) the tablet disintegrates in the mouth when placed on the
tongue in less than about 30 seconds.
[0007] In another aspect, the present invention features a process
for making a tablet comprising a first layer and a second layer,
the method including the steps of: (i) adding a first powder blend
to a die platen, wherein the first powder blend includes a
pharmaceutically active agent and a binder; (ii) adding a second
powder blend to the die platen, wherein the second powder blend
includes a binder and wherein the composition of the second powder
blend is different from the composition of the first powder blend;
(iii) compacting a first powder blend and a second powder blend in
the die platen to form a tablet shape; and (iv) applying energy to
the tablet shape for a sufficient period of time to activate the
binders within the tablet shape to fuse the tablet shape into the
tablet such that the tablet has a density less than about 0.8 g/cc
and the tablet disintegrates in the mouth when placed on the tongue
in less than about 30 seconds.
[0008] Other features and advantages of the present invention will
be apparent from the detailed description of the invention and from
the claims.
BRIEF DESCRIPTION OF THE FIGURES
[0009] FIGS. 1A-F are cross-section, side views of an embodiment of
the invention showing the manufacture of tablet 4a from powder
blend 4 within die platen 2.
[0010] FIGS. 2A-H are cross-section, side views of an embodiment of
the invention showing the manufacture of a bilayer tablet 12 from
powder blends 10 and 11 within die platen 2.
[0011] FIGS. 3A-G are cross-section, side views of an embodiment of
the invention showing the manufacture of tablet 40 containing
preformed inserts 30 and 31 from powder blend 20 within die platen
2.
[0012] FIGS. 4A and 4B are a perspective view of a rotary indexing
machine 195.
[0013] FIGS. 5A and 5B are top views of the rotary indexing machine
195 in the dwell position.
[0014] FIGS. 6A and 6B are section views of the lower forming tool
assembly 110 in the start position of the manufacturing cycle.
[0015] FIG. 7 is a section view through the RF station rotary
indexing machine 195 prior to compacting powder blend 101.
[0016] FIG. 8 is a section view through the RF station rotary
indexing machine 195 prior showing the manufacture of tablets
101a.
[0017] FIG. 9 is a section view through tablet ejection station 160
before tablets 101a have been ejected.
[0018] FIG. 10 is a section view through tablet ejection station
160 after tablets 101a have been ejected into blister 190.
[0019] FIGS. 11A-D are cross sections of alternate embodiments of
forming tools and the die platen.
[0020] FIGS. 12A-D are cross sections of alternate embodiments of
forming tools and the die platen.
[0021] FIG. 13A is a cross section of forming tools having a
wave-shaped surface.
[0022] FIG. 13B is a perspective view of forming tools having a
wave-shaped surface.
[0023] FIG. 14 is a cross section of forming tools having
protrusions at the surface.
DETAILED DESCRIPTION OF THE INVENTION
[0024] It is believed that one skilled in the art can, based upon
the description herein, utilize the present invention to its
fullest extent. The following specific embodiments can be construed
as merely illustrative, and not limitative of the remainder of the
disclosure in any way whatsoever.
[0025] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which the invention belongs. Also, all
publications, patent applications, patents, and other references
mentioned herein are incorporated by reference. As used herein, all
percentages are by weight unless otherwise specified.
[0026] As discussed above, in one aspect, the present invention
features a process for making a tablet by compacting a powder blend
in a die platen to form a tablet shape, wherein the powder blend
includes a pharmaceutically active agent and a meltable binder, and
applying radiofrequency energy to the tablet shape for a sufficient
period of time to soften or melt the binder within the tablet shape
to form the tablet.
Powder Blend
[0027] As discussed above, the tablet is manufactured by compacting
a powder blend containing a pharmaceutically active agent (as
discussed herein), a binder (as discussed herein), and optionally a
pharmaceutically-acceptable carrier. Examples of binders include
but are not limited to meltable binders and water-activating
binding materials. The carrier contains one or more suitable
excipients for the formulation of tablets. Examples of suitable
excipients include, but are not limited to, fillers, adsorbents,
disintegrants, lubricants, glidants, sweeteners,
superdisintegrants, flavor and aroma agents, antioxidants,
preservatives, texture enhancers, and mixtures thereof. One or more
of the above ingredients may be present on the same particle of the
powder blend.
[0028] Suitable fillers include, but are not limited to,
carbohydrates (as discussed herein) and water insoluble plastically
deforming materials (e.g., microcrystalline cellulose or other
cellulosic derivatives), and mixtures thereof.
[0029] Suitable adsorbents include, but are not limited to,
water-insoluble adsorbents such as dicalcium phosphate, tricalcium
phosphate, silicified microcrystalline cellulose (e.g., such as
distributed under the PROSOLV brand (PenWest Pharmaceuticals,
Patterson, N.Y.)), magnesium aluminometasilicate (e.g., such as
distributed under the NEUSILIN brand (Fuji Chemical Industries
(USA) Inc., Robbinsville, N.J.)), clays, silicas, bentonite,
zeolites, magnesium silicates, hydrotalcite, veegum, and mixtures
thereof.
[0030] Suitable disintegrants include, but are not limited to,
sodium starch glycolate, cross-linked polyvinylpyrrolidone,
cross-linked carboxymethylcellulose, starches, microcrystalline
cellulose, and mixtures thereof.
[0031] Suitable lubricants include, but are not limited to, long
chain fatty acids and their salts, such as magnesium stearate and
stearic acid, talc, glycerides waxes, and mixtures thereof.
[0032] Suitable glidants include, but are not limited to, colloidal
silicon dioxide.
[0033] Examples of sweeteners include, but are not limited to,
synthetic or natural sugars; artificial sweeteners such as
saccharin, sodium saccharin, aspartame, acesulfame, thaumatin,
glycyrrhizin, sucralose, dihydrochalcone, alitame, miraculin,
monellin, and stevside; sugar alcohols such as sorbitol, mannitol,
glycerol, lactitol, maltitol, and xylitol; sugars extracted from
sugar cane and sugar beet (sucrose), dextrose (also called
glucose), fructose (also called laevulose), and lactose (also
called milk sugar); isomalt, salts thereof, and mixtures
thereof.
[0034] Examples of superdisintegrants include, but are not limited
to, croscarmellose sodium, sodium starch glycolate and cross-linked
povidone (crospovidone). In one embodiment the tablet contains up
to about 5% by weight of such superdisintegrant.
[0035] Examples of flavors and aromatics include, but are not
limited to, essential oils including distillations, solvent
extractions, or cold expressions of chopped flowers, leaves, peel
or pulped whole fruit containing mixtures of alcohols, esters,
aldehydes and lactones; essences including either diluted solutions
of essential oils, or mixtures of synthetic chemicals blended to
match the natural flavor of the fruit (e.g., strawberry, raspberry
and black currant); artificial and natural flavors of brews and
liquors, e.g., cognac, whisky, rum, gin, sherry, port, and wine;
tobacco, coffee, tea, cocoa, and mint; fruit juices including
expelled juice from washed, scrubbed fruits such as lemon, orange,
and lime; spear mint, pepper mint, wintergreen, cinnamon,
cacoe/cocoa, vanilla, liquorice, menthol, eucalyptus, aniseeds nuts
(e.g., peanuts, coconuts, hazelnuts, chestnuts, walnuts, colanuts),
almonds, raisins; and powder, flour, or vegetable material parts
including tobacco plant parts, e.g., genus Nicotiana, in amounts
not contributing significantly to the level of nicotine, and
ginger.
[0036] Examples of antioxidants include, but are not limited to,
tocopherols, ascorbic acid, sodium pyrosulfite,
butylhydroxytoluene, butylated hydroxyanisole, edetic acid, and
edetate salts, and mixtures thereof.
[0037] Examples of preservatives include, but are not limited to,
citric acid, tartaric acid, lactic acid, malic acid, acetic acid,
benzoic acid, and sorbic acid, and mixtures thereof.
[0038] Examples of texture enhancers include, but are not limited
to, pectin, polyethylene oxide, and carrageenan, and mixtures
thereof. In one embodiment, texture enhancers are used at levels of
from about 0.1% to about 10% percent by weight.
[0039] In one embodiment of the invention, the powder blend has an
average particle size of less than 500 microns, such as from about
50 microns to about 500 microns, such as from about 50 microns and
300 microns. Particles in this size range are particularly useful
for direct compacting processes.
[0040] In one embodiment, the powder blend/tablet is substantially
free of superdisintegrants. As used herein, what is meant by
"substantially free" is less than 5%, such as less than 1%, such as
less than 0.1%, such as completely free (e.g., 0%). Examples of
superdisintegrants include, but are not limited to, starch
glycolate, cross-linked polyvinylpyrrolidone, and cross-linked
carboxymethylcellulose.
[0041] In one embodiment, powder blend/tablet is substantially free
of directly compressible water insoluble fillers. Water insoluble
fillers include but are not limited to microcrystalline cellulose,
directly compressible microcrystalline cellulose, celluloses, water
insoluble celluloses, starch, cornstarch and modified starches. As
described in this embodiment, substantially free is less than 2
percent, e.g. less than 1 percent or none.
Meltable Binder
[0042] In one embodiment, the powder blend/tablet of the present
invention includes at least one meltable binder. In one embodiment,
the meltable binder has a melting point of from about 30.degree. C.
to about 140.degree. C., such as from about 40.degree. C. to about
140.degree. C., such as from about 55.degree. C. to about
100.degree. C. The softening or melting of the meltable binder(s)
results in the sintering of the tablet shape through the binding of
the softened or melted binder with the pharmaceutically active
agent and/or other ingredients within the compacted powder
blend.
[0043] In one embodiment, the meltable binder is a RF-meltable
binder. What is meant by an RF-meltable binder is a solid binder
that can be softened or melted upon exposure to radiofrequency
("RF") energy. The RF-meltable binder typically is polar and has
the capability to re-harden or resolidify upon cooling.
[0044] In one embodiment, the RF meltable binder is not a
RF-meltable binder. In such embodiment, the powder blend contains
an excipient that heats upon exposure to RF energy (e.g., a polar
excipient), such that the resulting heat from is able to soften or
melt the meltable binder. Examples of such excipients include, but
are not limited to, polar liquids such as water and glycerin;
powdered metals and metal salts such as powdered iron, sodium
chloride, aluminum hydroxide, and magnesium hydroxide; stearic
acid; maltodextrin and sodium stearate.
[0045] Other examples of meltable binders include amorphous
carbohydrate polymers. What is meant by an "amorphous carbohydrate
polymer" is a molecule having a plurality of carbohydrate monomers
wherein such molecule has a crystallinity of less than 20%, such as
less than 10%, such as less than 5%. Examples of amorphous
carbohydrate polymers include, but are not limited to hydrogenated
starch hydrosolate, polydextrose, and oligosaccharides. Examples of
oligosaccharides include, but are not limited to,
fructo-oligosaccharide, galacto-oligosaccharide
malto-oligosaccharide, inulin, and isolmalto-oligosaccharide
[0046] Examples of suitable meltable binders include: fats such as
cocoa butter, hydrogenated vegetable oil such as palm kernel oil,
cottonseed oil, sunflower oil, and soybean oil; mono, di, and
triglycerides; phospholipids; cetyl alcohol; waxes such as Carnauba
wax, spermaceti wax, beeswax, candelilla wax, shellac wax,
microcrystalline wax, and paraffin wax; water soluble polymers such
as polyethylene glycol, polycaprolactone, GlycoWax-932, lauroyl
macrogol-32 glycerides, and stearoyl macrogol-32 glycerides;
polyethylene oxides; and sucrose esters.
[0047] In one embodiment, the meltable binder is a RF-meltable
binder, and the RF-meltable binder is a polyethylene glycol (PEG),
such as PEG-4000. A particularly preferred RF-meltable binder is
PEG having at least 95% by weight of the PEG particles less than
100 microns (as measured by conventional means such as light or
laser scattering or sieve analysis) and a molecular weight between
3000 and 8000 Daltons.
[0048] The meltable binder(s) may be present at level of about 0.01
percent to about 70 percent of the powder blend/tablet, such as
from about 1 percent to about 50 percent, such as from about 10
percent to about 30 percent of the powder blend/tablet.
[0049] In one embodiment, the average particle size of the binder
is less than 250 microns, such as less than 100 microns.
Water-Containing Material
[0050] In one embodiment, the powder blend/tablet of the present
invention includes at least one water-containing material. Examples
of water-containing materials include, but are not limited to,
materials wherein the water is chemically bound to the material
(e.g., a hydrate salt), materials wherein the water is adsorbed or
absorbed to the material (e.g., porous material such a silicas and
microsponges), and materials that have water encapsulated therein
(e.g., liquid filled capsules). Examples of such materials include,
but are not limited to: fumed silicas; colloidal silicas such as
colloidal silicon dioxide; silicates such as calcium silicate,
aluminum silicate, magnesium aluminum metasilicate (such as
NEUSILIN, US-2 from Fuji Chemical Ltd), and magnesium silicate;
clays; zeolites; and veegum.
[0051] In one embodiment, the powder blend/tablet contains at least
one hydrated salt. Examples of hydrated salts include, but are not
limited to, sodium sulfate hydrate, sodium carbonate hydrate,
calcium chloride hydrate, sodium hydrogen phosphate hydrate, and
mixtures thereof. In one embodiment, the hydrated salt has
molecular weight from about 150 to about 400 Daltons, such as from
about 200 to about 350 Daltons.
[0052] In one embodiment, the powder blend/tablet contains at least
one liquid filled capsule. In a further embodiment, the water is
released from the capsule upon rupture, wherein such rupture is
caused by the addition of energy.
[0053] The water-containing material(s) may be present at level of
about 0.01 percent to about 70 percent of the powder blend/tablet,
such as from about 1 percent to about 50 percent, such as from
about 1 percent to about 30 percent, such as from about 2 percent
to about 10 percent of the powder blend/tablet.
Water-Activating Binding Material
[0054] In one embodiment, the powder blend/tablet of the present
invention includes at least one water-activating binding material.
What is meant by a water-activating binding material is a material
that will activate or hydrate upon contact with water (e.g.
released from the water containing material upon the addition of
the energy) and assist in binding/fusing the powder blend into a
tablet. Examples of such materials include, but are not limited to,
hydrolyzed proteins, hydrating polymers and hydrocolloids. Suitable
hydrolyzed proteins include, but are not limited to, hydrolyzed
collagen. Suitable hydrating polymers include, but are not limited
to starches, modified starches, methylcellulose,
hydroxypropylcellulose, and hydroxypropylcellulose. Suitable
hydrocolloids include, but are not limited to, gelatin, gellan gum,
carrageenan, and pectin.
Carbohydrate
[0055] In one embodiment, the powder blend contains at least one
carbohydrate. The carbohydrate can contribute to the dissolvability
and mouth feel of the tablet, aid in distributing the meltable
binder across a broader surface area, and diluting and cushioning
the pharmaceutically active agent. In one embodiment, the
carbohydrate particles (e.g., sorbitol) act as the binder and are
sintered upon heating. Examples of carbohydrates include, but are
not limited to, water-soluble compressible carbohydrates such as
sugars (e.g., dextrose, sucrose, maltose, isomalt, and lactose),
starches (e.g., corn starch), sugar-alcohols (e.g., mannitol,
sorbitol, maltitol, erythritol, lactitol, and xylitol), and starch
hydrolysates (e.g., dextrins, and maltodextrins).
[0056] The carbohydrate(s) may be present at level of about 5
percent to about 95 percent of the powder blend/tablet, such as
from about 20 percent to about 90 percent or from about 40 percent
to about 80 percent of the powder blend/tablet. The particle size
of the of carbohydrate can influence the level of meltable binder
used, wherein a higher particle size of carbohydrate provides a
lower surface area and subsequently requires a lower level of
meltable binder. In one embodiment, wherein the carbohydrate(s) is
greater than 50% by weight of the powder blend and the mean
particle size of the carbohydrate(s) is greater than 100 microns,
then the meltable binder is from about 10 to about 30 percent by
weight of the powder blend/tablet.
Pharmaceutically Active Agent
[0057] The powder blend/tablet of the present invention includes at
least one pharmaceutically active agent. What is meant by a
"pharmaceutically active agent" is an agent (e.g., a compound) that
is permitted or approved by the U.S. Food and Drug Administration,
European Medicines Agency, or any successor entity thereof, for the
oral treatment of a condition or disease. Suitable pharmaceutically
active agents include, but are not limited to, analgesics,
anti-inflammatory agents, antipyretics, antihistamines, antibiotics
(e.g., antibacterial, antiviral, and antifungal agents),
antidepressants, antidiabetic agents, antispasmodics, appetite
suppressants, bronchodilators, cardiovascular treating agents
(e.g., statins), central nervous system treating agents, cough
suppressants, decongestants, diuretics, expectorants,
gastrointestinal treating agents, anesthetics, mucolytics, muscle
relaxants, osteoporosis treating agents, stimulants, nicotine, and
sedatives.
[0058] Examples of suitable gastrointestinal treating agents
include, but are not limited to: antacids such as
aluminum-containing pharmaceutically active agents (e.g., aluminum
carbonate, aluminum hydroxide, dihydroxyaluminum sodium carbonate,
and aluminum phosphate), bicarbonate-containing pharmaceutically
active agents, bismuth-containing pharmaceutically active agents
(e.g., bismuth aluminate, bismuth carbonate, bismuth subcarbonate,
bismuth subgallate, and bismuth subnitrate), calcium-containing
pharmaceutically active agents (e.g., calcium carbonate), glycine,
magnesium-containing pharmaceutically active agents (e.g.,
magaldrate, magnesium aluminosilicates, magnesium carbonate,
magnesium glycinate, magnesium hydroxide, magnesium oxide, and
magnesium trisilicate), phosphate-containing pharmaceutically
active agents (e.g., aluminum phosphate and calcium phosphate),
potassium-containing pharmaceutically active agents (e.g.,
potassium bicarbonate), sodium-containing pharmaceutically active
agents (e.g., sodium bicarbonate), and silicates; laxatives such as
stool softeners (e.g., docusate) and stimulant laxatives (e.g.,
bisacodyl); H2 receptor antagonists, such as famotidine,
ranitidine, cimetadine, and nizatidine; proton pump inhibitors such
as omeprazole, dextansoprazole, esomeprazole, pantoprazole,
rabeprazole, and lansoprazole; gastrointestinal cytoprotectives,
such as sucraflate and misoprostol; gastrointestinal prokinetics
such as prucalopride; antibiotics for H. pylori, such as
clarithromycin, amoxicillin, tetracycline, and metronidazole;
antidiarrheals, such as bismuth subsalicylate, kaolin,
diphenoxylate, and loperamide; glycopyrrolate; analgesics, such as
mesalamine; antiemetics such as ondansetron, cyclizine,
diphenyhydroamine, dimenhydrinate, meclizine, promethazine, and
hydroxyzine; probiotic bacteria including but not limited to
lactobacilli; lactase; racecadotril; and antiflatulents such as
polydimethylsiloxanes (e.g., dimethicone and simethicone, including
those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and
6,103,260); isomers thereof; and pharmaceutically acceptable salts
and prodrugs (e.g., esters) thereof.
[0059] Examples of suitable analgesics, anti-inflammatories, and
antipyretics include, but are not limited to, non-steroidal
anti-inflammatory drugs (NSAIDs) such as propionic acid derivatives
(e.g., ibuprofen, naproxen, ketoprofen, flurbiprofen, fenbufen,
fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen,
carprofen, oxaprozin, pranoprofen, and suprofen) and COX inhibitors
such as celecoxib; acetaminophen; acetyl salicylic acid; acetic
acid derivatives such as indomethacin, diclofenac, sulindac, and
tolmetin; fenamic acid derivatives such as mefanamic acid,
meclofenamic acid, and flufenamic acid; biphenylcarbodylic acid
derivatives such as diflunisal and flufenisal; and oxicams such as
piroxicam, sudoxicam, isoxicam, and meloxicam; isomers thereof; and
pharmaceutically acceptable salts and prodrugs thereof.
[0060] Examples of antihistamines and decongestants, include, but
are not limited to, bromopheniramine, chlorcyclizine,
dexbrompheniramine, bromhexane, phenindamine, pheniramine,
pyrilamine, thonzylamine, pripolidine, ephedrine, phenylephrine,
pseudoephedrine, phenylpropanolamine, chlorpheniramine,
dextromethorphan, diphenhydramine, doxylamine, astemizole,
terfenadine, fexofenadine, naphazoline, oxymetazoline, montelukast,
propylhexadrine, triprolidine, clemastine, acrivastine,
promethazine, oxomemazine, mequitazine, buclizine, bromhexine,
ketotifen, terfenadine, ebastine, oxatamide, xylomeazoline,
loratadine, desloratadine, and cetirizine; isomers thereof; and
pharmaceutically acceptable salts and esters thereof.
[0061] Examples of cough suppressants and expectorants include, but
are not limited to, diphenhydramine, dextromethorphan, noscapine,
clophedianol, menthol, benzonatate, ethylmorphone, codeine,
acetylcysteine, carbocisteine, ambroxol, belladona alkaloids,
sobrenol, guaiacol, and guaifenesin; isomers thereof; and
pharmaceutically acceptable salts and prodrugs thereof.
[0062] Examples of muscle relaxants include, but are not limited
to, cyclobenzaprine and chlorzoxazone metaxalone, orphenadrine, and
methocarbamol; isomers thereof; and pharmaceutically acceptable
salts and prodrugs thereof.
[0063] Examples of stimulants include, but are not limited to,
caffeine.
[0064] Examples of sedatives include, but are not limited to sleep
aids such as antihistamines (e.g., diphenhydramine), eszopiclone,
and zolpidem, and pharmaceutically acceptable salts and prodrugs
thereof.
[0065] Examples of appetite suppressants include, but are not
limited to, phenylpropanolamine, phentermine, and diethylcathinone,
and pharmaceutically acceptable salts and prodrugs thereof.
[0066] Examples of anesthetics (e.g., for the treatment of sore
throat) include, but are not limited to dyclonine, benzocaine, and
pectin and pharmaceutically acceptable salts and prodrugs
thereof.
[0067] Examples of suitable statins include but are not limited to
atorvastin, rosuvastatin, fluvastatin, lovastatin, simvustatin,
atorvastatin, pravastatin and pharmaceutically acceptable salts and
prodrugs thereof.
[0068] In one embodiment, the pharmaceutically active agent
included within the tablet is selected from phenylephrine,
dextromethorphan, pseudoephedrine, acetaminophen, cetirizine,
aspirin, nicotine, ranitidine, ibuprofen, ketoprofen, loperamide,
famotidine, calcium carbonate, simethicone, chlorpheniramine,
methocarbomal, chlophedianol, ascorbic acid, pectin, dyclonine,
benzocaine and menthol, and pharmaceutically acceptable salts and
prodrugs thereof.
[0069] As discussed above, the pharmaceutically active agents of
the present invention may also be present in the form of
pharmaceutically acceptable salts, such as acidic/anionic or
basic/cationic salts. Pharmaceutically acceptable acidic/anionic
salts include, and are not limited to acetate, benzenesulfonate,
benzoate, bicarbonate, bitartrate, bromide, calcium edetate,
camsylate, carbonate, chloride, citrate, dihydrochloride, edetate,
edisylate, estolate, esylate, fumarate, glyceptate, gluconate,
glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine,
hydrobromide, hydrochloride, hydroxynaphthoate, iodide,
isethionate, lactate, lactobionate, malate, maleate, mandelate,
mesylate, methylbromide, methylnitrate, methylsulfate, mucate,
napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate,
polygalacturonate, salicylate, stearate, subacetate, succinate,
sulfate, tannate, tartrate, teoclate, tosylate and triethiodide.
Pharmaceutically acceptable basic/cationic salts include, and are
not limited to aluminum, benzathine, calcium, chloroprocaine,
choline, diethanolamine, ethylenediamine, lithium, magnesium,
meglumine, potassium, procaine, sodium and zinc.
[0070] As discussed above, the pharmaceutically active agents of
the present invention may also be present in the form of prodrugs
of the pharmaceutically active agents. In general, such prodrugs
will be functional derivatives of the pharmaceutically active
agent, which are readily convertible in vivo into the required
pharmaceutically active agent. Conventional procedures for the
selection and preparation of suitable prodrug derivatives are
described, for example, in "Design of Prodrugs", ed. H. Bundgaard,
Elsevier, 1985. In addition to salts, the invention provides the
esters, amides, and other protected or derivatized forms of the
described compounds.
[0071] Where the pharmaceutically active agents according to this
invention have at least one chiral center, they may accordingly
exist as enantiomers. Where the pharmaceutically active agents
possess two or more chiral centers, they may additionally exist as
diastereomers. It is to be understood that all such isomers and
mixtures thereof are encompassed within the scope of the present
invention. Furthermore, some of the crystalline forms for the
pharmaceutically active agents may exist as polymorphs and as such
are intended to be included in the present invention. In addition,
some of the pharmaceutically active agents may form solvates with
water (e.g., hydrates) or common organic solvents, and such
solvates are also intended to be encompassed within the scope of
this invention.
[0072] In one embodiment, the pharmaceutically active agent or
agents are present in the tablet in a therapeutically effective
amount, which is an amount that produces the desired therapeutic
response upon oral administration and can be readily determined by
one skilled in the art. In determining such amounts, the particular
pharmaceutically active agent being administered, the
bioavailability characteristics of the pharmaceutically active
agent, the dose regime, the age and weight of the patient, and
other factors must be considered, as known in the art.
[0073] The pharmaceutically active agent may be present in various
forms. For example, the pharmaceutically active agent may be
dispersed at the molecular level, e.g. melted, within the tablet,
or may be in the form of particles, which in turn may be coated or
uncoated. If the pharmaceutically active agent is in form of
particles, the particles (whether coated or uncoated) typically
have an average particle size of from about 1 to about 2000
microns. In one embodiment, such particles are crystals having an
average particle size of from about 1 to about 300 microns. In
another embodiment, the particles are granules or pellets having an
average particle size of from about 50 to about 2000 microns, such
as from about 50 to about 1000 microns, such as from about 100 to
about 800 microns.
[0074] The pharmaceutically active agent may be present in pure
crystal form or in a granulated form prior to the addition of the
taste masking coating. Granulation techniques may be used to
improve the flow characteristics or particle size of the
pharmaceutically active agents to make it more suitable for
compaction or subsequent coating. Suitable binders for making the
granulation include but are not limited to starch,
polyvinylpyrrolidone, polymethacrylates,
hydroxypropylmethylcellulose, and hydroxypropylcellulose. The
particles including pharmaceutically active agent(s) may be made by
cogranulating the pharmaceutically active agent(s) with suitable
substrate particles via any of the granulation methods known in the
art. Examples of such granulation method include, but are not
limited to, high sheer wet granulation and fluid bed granulation
such as rotary fluid bed granulation.
[0075] If the pharmaceutically active agent has an objectionable
taste, the pharmaceutically active agent may be coated with a taste
masking coating, as known in the art. Examples of suitable taste
masking coatings are described in U.S. Pat. No. 4,851,226, U.S.
Pat. No. 5,075,114, and U.S. Pat. No. 5,489,436. Commercially
available taste masked pharmaceutically active agents may also be
employed. For example, acetaminophen particles, which are
encapsulated with ethylcellulose or other polymers by a
coacervation process, may be used in the present invention.
Coacervation-encapsulated acetaminophen may be purchased
commercially from Eurand America, Inc. (Vandalia, Ohio) or from
Circa Inc. (Dayton, Ohio).
[0076] In one embodiment, the tablet incorporates modified release
coated particles (e.g., particles containing at least one
pharmaceutically active agent that convey modified release
properties of such agent). As used herein, "modified release" shall
apply to the altered release or dissolution of the active agent in
a dissolution medium, such as gastrointestinal fluids. Types of
modified release include, but are not limited to, sustained release
or delayed release. In general, modified release tablets are
formulated to make the active agents(s) available over an extended
period of time after ingestion, which thereby allows for a
reduction in dosing frequency compared to the dosing of the same
active agent(s) in a conventional tablet. Modified release tablets
also permit the use of active agent combinations wherein the
duration of one pharmaceutically active agent may differ from the
duration of another pharmaceutically active agent. In one
embodiment the tablet contains one pharmaceutically active agent
that is released in an immediate release manner and an additional
active agent or a second portion of the same active agent as the
first that is modified release.
[0077] Examples of swellable, erodible hydrophilic materials for
use as a release modifying excipient for use in the modified
release coating include water swellable cellulose derivatives,
polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic
polymers, hydrocolloids, clays, and gelling starches. Examples of
water swellable cellulose derivatives include sodium
carboxymethylcellulose, cross-linked hydroxypropylcellulose,
hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC),
hydroxyisopropylcellulose, hydroxybutylcellulose,
hydroxyphenylcellulose, hydroxyethylcellulose (HEC),
hydroxypentylcellulose, hydroxypropylethylcellulose,
hydroxypropylbutylcellulose, and hydroxypropylethylcellulose.
Examples of polyalkylene glycols include polyethylene glycol.
Examples of suitable thermoplastic polyalkylene oxides include poly
(ethylene oxide). Examples of acrylic polymers include potassium
methacrylatedivinylbenzene copolymer, polymethylmethacrylate, and
high-molecular weight cross-linked acrylic acid homopolymers and
copolymers.
[0078] Suitable pH-dependent polymers for use as release-modifying
excipients for use in the modified release coating include: enteric
cellulose derivatives such as hydroxypropyl methylcellulose
phthalate, hydroxypropyl methylcellulose acetate succinate, and
cellulose acetate phthalate; natural resins such as shellac and
zein; enteric acetate derivatives such as polyvinylacetate
phthalate, cellulose acetate phthalate, and acetaldehyde
dimethylcellulose acetate; and enteric acrylate derivatives such as
for example polymethacrylate-based polymers such as
poly(methacrylic acid, methyl methacrylate) 1:2 (available from
Rohm Pharma GmbH under the tradename EUDRAGIT S) and
poly(methacrylic acid, methyl methacrylate) 1:1 (available from
Rohm Pharma GmbH under the tradename EUDRAGIT L).
[0079] In one embodiment the pharmaceutically active agent is
coated with a combination of a water insoluble film forming polymer
(such as but not limited to cellulose acetate or ethylcellulose)
and a water soluble polymer (such as but not limited to povidone,
polymethacrylic co-polymers such as those sold under the tradename
Eudragit E-100 from Rohm America, and hydroxypropylcellulose). In
this embodiment, the ratio of water insoluble film forming polymer
to water soluble polymer is from about 50 to about 95 percent of
water insoluble polymer and from about 5 to about 50 percent of
water soluble polymer, and the weight percent of the coating by
weight of the coated taste-masked particle is from about 5 percent
to about 40 percent. In one embodiment, the coating which is used
in the coated particle of the pharmaceutically active agent is
substantially free of a material (such as polyethylene glycol)
which melts below 85.degree. C., in order to prevent damage to the
integrity of the coating during the RF heating step.
[0080] In one embodiment, one or more pharmaceutically active
agents or a portion of the pharmaceutically active agent may be
bound to an ion exchange resin for the purposes of taste-masking
the pharmaceutically active agent or delivering the active in a
modified release manner.
[0081] In one embodiment, the pharmaceutically active agent is
capable of dissolution upon contact with a fluid such as water,
stomach acid, intestinal fluid or the like. In one embodiment, the
dissolution characteristics of the pharmaceutically active agent
within the tablet meets USP specifications for immediate release
tablets including the pharmaceutically active agent. For example,
for acetaminophen tablets, USP 24 specifies that in pH 5.8
phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at
least 80% of the acetaminophen contained in the tablet is released
there from within 30 minutes after dosing, and for ibuprofen
tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using
USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen
contained in the tablet is released there from within 60 minutes
after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999). In
another embodiment, the dissolution characteristics of the
pharmaceutically active agent are modified: e.g. controlled,
sustained, extended, retarded, prolonged, delayed and the like.
[0082] In one embodiment, the particle size of the pharmaceutically
active agent causes more void spaces to be present in the tablet,
wherein a higher particle size of the pharmaceutically active agent
subsequently requires a lower level of meltable binder. In one
embodiment, wherein the pharmaceutically active agent or coated
pharmaceutically active agent(s) is greater than 50% of the blend
by weight of the powder blend/tablet and the mean particle size of
the carbohydrate is greater than 100 microns, the meltable binder
is from about 10 to about 30 percent by weight of the powder
blend/tablet. In one embodiment, wherein the mean particle size of
the powder blend is between about 100 microns and about 300
microns, then meltable binder is from about 10 to about 20 percent
by weight of the powder blend/tablet.
[0083] The melting point of the pharmaceutically active agent can
have an impact on the temperature used during the heating step and
the type of meltable binder used. In one embodiment, the melting
point of the meltable binder is less than the melting point of the
pharmaceutically active agent. In another embodiment, the melting
point of the pharmaceutically active agent is the same or lower
than the melting point of the meltable binder, in which case during
the fusing or heating step, both the pharmaceutically active agent
and the meltable binder may melt and create a eutectic or various
bridges of the pharmaceutically active agent and meltable binder
between the other materials in the tablet form upon cooling. In one
embodiment, the heating temperature is above the melting point of
the meltable binder and below the melting point of the
pharmaceutically active agent. In one embodiment wherein ibuprofen
is the pharmaceutically active agent, the meltable binder is heated
from about 30.degree. C. to about 60.degree. C. In one embodiment,
the pharmaceutically active agent is the meltable binder.
[0084] In one embodiment, the pharmaceutically active agent is in
the form of a particle that is coated with the binder. Examples of
such binder coated particles include, but are not limited to,
meltable materials such as glyceryl palmitostearate.
[0085] The susceptibility to RF energy of the pharmaceutically
active agent (e.g., to melt or degrade) can have an impact on the
type of energy and/or temperature used during the heating step as
well as the type of the meltable binder used.
[0086] In one embodiment, the processing of the tablet is free of a
wet or hot melt granulation step. In this embodiment, the materials
are directly blended prior to the addition of heat. In one
embodiment, the materials are directly blended and compressed prior
to the addition of heat.
Manufacture of Tablet Shape
[0087] In one embodiment, the tablet shape is pre-formed by light
compaction. In one embodiment, the powder blend is fed into the
tablet die of an apparatus that applies pressure to form the tablet
shape (e.g., by light compaction such as tamping). Any suitable
compacting apparatus may be used, including, but not limited to, a
conventional unitary or rotary tablet press. In one embodiment, the
tablet shape may be formed by compaction using a rotary tablet
press (e.g., such as those commercially available from Fette
America Inc., Rockaway, N.J. or Manesty Machines LTD, Liverpool,
UK). In one embodiment, the tablet shape is heated after it is
removed from the tablet press. In another embodiment, the tablet
shape is heated within the tablet press.
[0088] In one embodiment, to obtain desired attribute of an orally
disintegrating tablet, the tablet's construction may be highly
porous, use a minimal amount of binder, and/or have a low density.
Such tablets, therefore, are somewhat fragile and soft. In a
preferred embodiment, a minimum of tamping/compaction force is
desired to achieve the orally disintegrating property (low
density). Experiments have determined that low force compaction
without application of energy produced very fragile tablets that
could not withstand the forces of material handling required in
manufacturing.
[0089] In most thermodynamic processes or machines, the heat source
and the heat sink are two distinct machines or steps requiring
material to be transferred from one apparatus to the other. In the
manufacture of the tablets of the present invention, the energy
must be added to the tablet to achieve the binding effect and then
must be removed from the product to solidify and strengthen it for
its final handling packaging and use. One of the unique and
unanticipated attributes of one embodiment of the manufacturing
process of the present invention is that heat source and heat sink
are part of the same apparatus. In fact in early experiments the
metallic forming tool (e.g., a die punch) which was at room
temperature removed so much heat from the treated tablet shape (due
to its high thermal conductivity) that the surface of the resulting
tablet was unacceptable due to the fact that uniform melting within
the powder blend had not taken place. The resulting tablet had a
well formed core, but the surface was loose unbound and poorly
formed powder that did not adhere to the rest of the tablet. To
correct for this thermal loss, in one embodiment, heat is added to
the forming tools to achieve proper sintering at the surface as
well as at the center of the tablet.
[0090] To exploit this unique thermal effect, powder blends can
also be chosen for their thermal properties and thermal
conductivity and specific heat such that the powder blend particles
themselves become heat sinks. For example, in a typical ODT
formulation the polar binders that heat in the RF field may compose
less than 10% of the mixture. The remaining 90% of the materials
act as a heat sink that quickly removes heat from the binders once
the RF field is removed. The desirable result of this is that the
total process time can be just a few seconds and that the tablet
does not need to be transferred from the die platen during the
critical tamping and heating process. The die platen can function
then as a material handling apparatus as well as a thermal forming
tool. This is particularly advantageous for successful manufacture
of fragile orally disintegrating tablets.
[0091] In one embodiment, the compaction step (e.g., tamping) which
occurs prior to the addition of the energy utilizes a compaction
force which is less than the force required to compress a chewable
or swallowable tablet. In one embodiment, the compaction force is
less than about 1000 pounds per square inch (e.g., less than about
500 pounds per square inch, such as less than 200 pounds per square
inch, such as less than 50 pounds per square inch). In one
embodiment, the energy is applied while the powder blend is under
such force.
[0092] In one embodiment, the compaction step occurs in an indexed
manner, where one set of tablets are compacted simultaneously,
before rotating to another indexing station. In one embodiment, the
compaction step occurs at a single indexing station and the
application of energy occurs at a separate indexing station. In
another embodiment, a third indexing station is present wherein the
ejection of the tablet or multiple tablets occurs, wherein the
lower forming tool is raised up through and up to the surface of
the die. In another embodiment the compaction step is performed
through the addition of air pressure or hydraulic cylinder to the
top of the upper forming tools. In one embodiment multiple tablets
are ejected simultaneously and separated from the surface of the
indexing station and removed via a take-off bar.
[0093] In another embodiment, the tablet shape may be prepared by
the compaction methods and apparatus described in United States
Patent Application Publication No. 20040156902. Specifically, the
tablet shape may be made using a rotary compression module
including a fill zone, insertion zone, compression zone, ejection
zone, and purge zone in a single apparatus having a double row die
construction. The dies of the compression module may then be filled
using the assistance of a vacuum, with filters located in or near
each die. The purge zone of the compression module includes an
optional powder blend recovery system to recover excess powder
blend from the filters and return the powder blend to the dies. In
one embodiment the energy source (e.g., RF energy source) is
projected through the die table of a rotary press into the
appropriate electrode within the forming tool or the forming
cavity. In one embodiment the die table is constructed of
non-conductive material.
[0094] In another embodiment, a portion of the tablet shape may be
prepared by a wet-granulation method, in which the excipients and a
solution or dispersion of a wet binder (e.g., an aqueous cooked
starch paste or solution of polyvinyl pyrrolidone) are mixed and
granulated. Suitable apparatus for wet granulation include low
shear mixers (e.g., planetary mixers), high shear mixers, and fluid
beds (including rotary fluid beds). The resulting granulated
material may then be dried, and optionally dry-blended with further
ingredients (e.g., excipients such as, for example, the binders
described in the invention herein, lubricants, colorants, and the
like). The final dry blend is then suitable for compaction by the
methods described herein. Methods for direct compaction and wet
granulation processes are known in the art.
[0095] In one embodiment, the tablet shape is prepared by the
compaction methods and apparatus described in issued U.S. Pat. No.
6,767,200. Specifically, the tablet shape is made using a rotary
compression module including a fill zone, compression zone, and
ejection zone in a single apparatus having a double row die
construction as shown in FIG. 6 therein. The dies of the
compression module are preferably filled using the assistance of a
vacuum, with filters located in or near each die.
[0096] The tablet shape may have one of a variety of different
shapes. For example, the tablet shape may be shaped as a
polyhedron, such as a cube, pyramid, prism, or the like; or may
have the geometry of a space figure with some non-flat faces, such
as a cone, truncated cone, triangle, cylinder, sphere, torus, or
the like. In certain embodiments, a tablet shape has one or more
major faces. For example, the tablet shape surface typically has
opposing upper and lower faces formed by contact with the upper and
lower forming tool faces (e.g., die punches) in the compaction
machine. In such embodiments, the tablet shape surface typically
further includes a "belly-band" located between the upper and lower
faces, and formed by contact with the die walls in the compaction
machine. A tablet shape/tablet may also be a multilayer. Applicants
have found that sharp edges in the tooling used to make the tablets
can cause arcing, and thus more rounded edges may be needed.
[0097] In one embodiment, the method of producing the tablet shape
is substantially free of the use of solvents. In this embodiment,
the powder blend is substantially free of solvents, and the
manufacturing process (e.g., filling process into the die) is also
substantially free of solvents. Solvents may include, but are not
limited to, water, organic solvents such as but not limited to
alcohols, chlorinated solvents, hexanes, or acetone; or gaseous
solvents such as but not limited to nitrogen, carbon dioxide or
supercritical fluids.
[0098] In one embodiment a vibratory step is utilized (e.g., added
after filling of the powder blend but prior to the heating or
fusing step, in order to remove air from the powder blend). In one
embodiment a vibration with the frequency from about 1 Hz to about
50 KHz is added with amplitude from 1 micron to 5 mm peak-to-peak
to allow for the flowable powder blend to settle into the cavity of
a the die platen ("forming cavity").
[0099] In one embodiment, as shown in FIGS. 1A-1F, a metered volume
of powder blend 4 is filled into a Teflon.RTM. (or similar
electrical and RF energy insulative material such as ceramic or
UHMW plastic) die platen 2. Die platen 2 has forming cavity 5 with
inner wall 6, upper opening 7 on the upper surface of die platen 2
(which allows powder blend 4 and upper forming tool 1 to move into
the forming cavity 5), and lower opening 8 on the opposite surface
of die platen 2 (which allows powder blend 4 and lower forming tool
3 to move into the forming cavity 5). Powder blend 4 may be either
gravity fed or mechanically fed from a feeder (not shown). A
metallic, electrically conductive lower forming tool 3 is inserted
into the die platen to retain the powder blend 4, within die platen
2. A similar metallic, electrically conductive upper forming tool 1
is positioned above the die platen 2 as shown in FIG. 1B. The
forming tools 1 and 3, die platen 2, and powder blend 4 are then
moved to a compaction and RF heating station as shown in FIG. 1C to
form tablet shape 4a.
[0100] This heating station is comprised of an RF generator 7 which
produces the necessary high voltage, high frequency energy. The
generator 7 is electrically connected to movable upper RF electrode
plate 8 and movable lower RF electrode plate 6. As shown in FIG.
1C, at this position, the powder blend 4 is compacted between an
upper forming tool 1 and a lower forming tool 3 by pressure exerted
by upper RF electrode plate 8 and lower electrode plate 6 to form
tablet shape 4a. Tablet shape 4a is then exposed to RF energy from
RF generator 7, which heats the meltable binder within tablet shape
4a. After the RF energy is switched off, tablet shape 4a cools to
form the tablet 4b. In one embodiment, as shown in FIG. 1D, tablet
4b is pushed by upper forming tool 1 from the die platen 2 into
blister 8, which is used to package tablet 4b. In an alternative
embodiment, as shown in FIG. 1E, tablet 4b is pushed from the die
platen 2 by the lower forming tool 3 and guided to an ejection
chute by a stationary "take-off" bar (not shown). FIG. 1F shows a 3
dimensional representation of the forming tools 1 and 4, die platen
2, and tablet 4b.
[0101] In FIGS. 2A-2H, an alternate embodiment of the invention is
shown where a multilayer tablet is produced. First, powder blend 10
is filled into die platen 2 as shown in FIG. 2A. Powder blend 10 is
tamped or moved down into die platen 2 by upper forming tool 1 as
shown in FIG. 2B to form tablet shape 10a. Then, powder blend 11 is
then filled on top of tablet shape 10a. The forming tools 1 and 3,
die platen 2, tablet shape 10a and powder blend 11 are then moved
to the compaction and RF heating station as shown in FIG. 2E. RF
heating is accomplished as described above in FIG. 1C to produce
multilayer tablet 12 as shown in FIGS. 2F and 2G. While a bi-layer
tablet is shown in the drawing, additional multiple layers can be
produced by adding additional powder blends to die platen 2.
[0102] FIGS. 3A-3G show another embodiment of the invention where
preformed inserts 30 and 31 are inserted into tablet shape 20a as
shown in FIGS. 3A-3D. Forming tools 1 and 3, die platen 2, tablet
shape 20, and preformed inserts 30 and 31 are then moved to the
compaction and RF heating station as shown in FIG. 3E. RF heating
is accomplished as described above in FIG. 1C to produce a
multi-component tablet 40 shown in FIGS. 2F and 2G.
[0103] FIGS. 4A and 4B show two views of a rotary indexing machine
195 which is designed to create large quantities of tablets. In
particular, the configuration of the apparatus shown is designed to
manufacture fragile tablets with minimized risk of damaging them as
they are moved through the various manufacturing steps. This
embodiment of the invention is comprised of an indexing table 170
having four sets of die platens 175 each having sixteen cavities,
powder feeder 100, RF generator 150, a machine frame 140, moving RF
electrode assemblies 120 and 130, lower forming tool assembly 110,
upper forming tool assembly 210, tablet ejection station 160,
indexer drive system 180, blister package web 190, and blister lid
material roll 191.
[0104] FIG. 5A is a top view of the apparatus in the dwell
position. FIG. 5B is a top view of the apparatus as the indexing
table 170 rotates between stations in direction "A". FIG. 6A
depicts a section view through the lower forming tool assembly 110
in a start position of the manufacturing cycle. The lower forming
tools 111, which are made of an electrically conductive metallic
material such as brass or stainless steel, are retained in retainer
plate 112 (e.g., made of aluminum or steel). Heated block 117 is
attached to the retainer plate 112 and contains fluid passages
117b. Heated (or optionally cooling) fluid is circulated through
the heated block 117 by connections to flexible hoses 119a and 119b
which form a supply and return circuit. Heating can also be
accomplished by electric cartridge heaters or other suitable means
(not shown). Attached to the retainer plate are cam-follower 114
and linear bearing 113. A guide shaft 116 is fixed to indexing
table 170. The retainer plate and forming tools 111 and are
moveable up or down according to the profile of barrel cam 115
which cam follower 114 rolls upon. Also shown is die platen 171,
which is made of electrical and RF energy insulative material such
as Teflon, UHMW, or ceramic. This is necessary to prevent a short
circuit when the electrically conductive forming tools are
positioned in the RF electric field in subsequent steps. The
forming cavity 171a is shown empty at this stage of the
process.
[0105] FIG. 6B depicts a section through the powder feeder station
100 of the apparatus. In this station powdered powder blend 101 is
gravity fed into die platen 171. Movable cam segment 118 is
adjusted up or down in direction "B" to vary the volume of the
forming cavity 171a by changing the amount that the lower forming
tools 111 penetrate into the die platen 171. This adjustable volume
feature enables the precise dose of powdered powder blend to be
selected for a desired tablet weight. When the machine indexes out
of the powder feeder station, the rim of feeder 102 scrapes against
the die platen 171 to create a level powder surface relative to the
surface of the die platen 171.
[0106] FIG. 7 is a section view through the RF station of the
apparatus. The RF generator 150 is depicted symbolically here. In
one embodiment, the configuration of the RF generator 150 is a free
running oscillator system. It is typically composed of a power
vacuum tube (such as a triode), a DC voltage source between 1000
and 8000 volts connected across the cathode and plate (anode). A
tank circuit is used to impose a sinusoidal signal upon the control
grid and electrodes thereby producing the necessary frequency
(typically 13.56 MHZ or 27.12 MHZ) and high voltage field. An
example of such RF generator 150 is the COSMOS Model C10X16G4
(Cosmos Electronic Machine Corporation, Farmingdale, N.Y.). In
another embodiment, RF energy can be provided by a 50 Ohm system
composed of a waveform generator which feeds a radio frequency
signal to power amplifiers which are coupled to the electrodes and
the load by an impedance matching network.
[0107] In FIG. 7, a lower movable RF electrode 121 is shown,
movable in direction "D". It is represented in its down position.
The linear movement is generated by linear actuators which are
typically devises such as air cylinders or servo motors. Two air
cylinders are depicted in FIG. 7. Air cylinder bodies 141 and 142
apply pressure to guide rods 144 and 143. Moving platens 132 and
122 are connected to the guide rods and provide an electrically
isolated mounting for electrode plates 131 and 121. RF generator
150 connects to the electrode plates 131 and 121 through wires 185
and 184. A movable upper RF electrode assembly 130, movable in
direction "C", is shown in its up position. Upper forming tools
133, retainer plate 134, and heated block 135 are all attached to
the movable RF electrode plate 131 and, consequently, move up and
down with it. Powder blend 101 is within die platen 171.
[0108] FIG. 8 is a section through the same RF station but shows
the RF electrodes 131 and 121 pressing against the respective
forming tool assemblies 133 and 111 to both compact and apply RF
energy to powder blend 101 creating tablet 101a. After application
of the RF energy is stopped, the moveable RF electrode plates
retract, and the indexing plate 170, die platen 171, and lower
forming tool assembly 110 are indexed to the next station.
[0109] FIG. 9 is a section view through the tablet ejection station
160. Ejector pins 161 are attached to movable plate 162 (movable in
the "E" direction), which is actuated by actuator assembly 163 (for
example, this can be a linear servo motor or air cylinder or other
suitable actuator). Actuator rod 166 connects to the movable plate
162. Linear bearing 164 and guide rod 165 provide rigidity and
support for the actuator plate 162 and prevent destructive side
loads created by the ejection force from acting upon actuator 163.
A blister package 190 is shown below die platen 171.
[0110] FIG. 10 is a section through the same assembly after the
ejector pins 161 have pushed finished tablets 101a through the die
platen 171. This direct placement of tablet into blister helps
prevent breakage that could occur while using typical means such as
feeders or by dumping tablets into transport drums.
[0111] In one embodiment, a lubricant is added to forming cavity
prior to the addition of the flowable powder blend. This lubricant
may be a liquid or solid. Suitable lubricants include but are not
limited to solid lubricants such as magnesium stearate, starch,
calcium stearate, aluminum stearate and stearic acid; or liquid
lubricants such as but not limited to simethicone, lecithin,
vegetable oil, olive oil, or mineral oil. In certain embodiments,
the lubricant is added at a percentage by weight of the tablet of
less than 5 percent, e.g. less than 2 percent, e.g. less than 0.5
percent. In certain embodiments, the presence of a hydrophobic
lubricant can disadvantageously compromise the disintegration or
dissolution properties of a tablet. In one embodiment the tablet is
substantially free of a hydrophobic lubricant. Hydrophobic
lubricants include magnesium stearate, calcium stearate and
aluminum stearate.
Heating of Tablet Shape to Form Tablet
[0112] Various forms of energy may be used in the process to
activate the binder. Suitable sources of energy include but are not
limited to convection, radio frequency, microwave, UV light,
infrared, induction, laser light, and ultrasonic sound. In one
embodiment, radiofrequency energy is used. Radiofrequency heating
generally refers to heating with electromagnetic field at
frequencies from about 1 MHz to about 100 MHz. In one embodiment of
the present invention, the RF-energy is within the range of
frequencies from about 1 MHz to about 100 MHz (e.g., from about 5
MHz to 50 MHz, such as from about 10 MHz to about 30 MHz).
[0113] In one embodiment, RF-energy is used to heat the binder
(e.g., either directly when the meltable binder is a RF-meltable
binder or indirectly when the meltable binder is not a RF meltable
binder but is heated by a RF-heatable ingredient within the powder
blend). The degree of compaction, the type and amount of meltable
binder, and the amount of RF energy used can determine the hardness
and/or type of tablet whether an oral disintegrating tablet or a
soft chewable tablet is manufactured.
[0114] RF energy generators are well known in the art. Examples of
suitable RF generators include, but are not limited to, COSMOS
Model C10X16G4 (Cosmos Electronic Machine Corporation, Farmingdale,
N.Y.).
[0115] The energy (e.g., RF energy) is used to activate the binder.
The degree of compaction, the type and amount of binder, and the
amount of energy used can determine the hardness and/or type of
tablet.
[0116] In one embodiment, when RF energy is used, the upper and
lower forming tools serve as the electrodes (e.g., they are
operably associated with the RF energy source) through which the RF
energy is delivered to the tablet shape. In one embodiment, there
is direct contact between at least one RF electrode (e.g., forming
tool) and the tablet shape. In another embodiment, there is no
contact between any of the RF electrode (e.g., forming tools) and
the tablet shape. In one embodiment, the RF electrodes are in
direct contact with the surface of the tablet shape when the RF
energy is added. In another embodiment, the RF electrodes are not
in contact (e.g., from about 1 mm to about 1 cm from the surface of
the tablet shape) during the addition of the RF energy.
[0117] In one embodiment, the RF energy is delivered while the
tablet shape is being formed. In one embodiment, the RF energy is
delivered once the tablet shape is formed. In one embodiment, the
RF energy is delivered after the tablet shape has been removed from
the die.
[0118] In one embodiment, the RF energy is applied for a sufficient
time to soften and melt substantially all (e.g., at least 90%, such
as at least 95%, such as all) of the binder within the tablet
shape. In one embodiment, the RF energy is applied for a sufficient
time to soften and melt only a portion (e.g., less than 75%, such
as less than 50%, such as less than 25%) of the binder within the
tablet shape, for example only on a portion of the tablet shape,
such as the outside of the tablet shape.
[0119] In alternate embodiments of the invention, the forming tools
can be constructed to achieve localized heating effects and can
also be configured to shape the electric field that is developed
across the tools. FIG. 11A shows one such configuration. An RF
generator 200 is connected to RF electrode plates 201 and 202.
Forming tools 205 and 204 are constructed of an electrically
conductive material and they have an attachment 207 and 208 which
are made of electrical and RF energy insulative material such as
ceramic, Teflon.RTM., polyethylene, or high density polyethylene.
Die platen 203 is also constructed of electrical and RF energy
insulative material. This configuration creates greater distance
between the conductive forming tools to weaken the electric field
which is beneficial for producing thin tablets without the risk of
an electric arc forming which would damage the product and tooling.
FIG. 11B depicts a similar configuration but with forming tools 210
and 211 that, respectively, have a recess containing insert 213 and
212 which are made of electrical and RF energy insulative material.
This geometry will produce a tablet with lesser heating in the area
where the inserts 213 and 212 are located since the electric field
is weaker due to the greater distance between the conductive
portions of 211 and 210. FIG. 11C is similar to FIG. 11B only the
geometry is reversed so the tablet formed by this configuration
will have a greater heating effect at the center since the inserts
216 and 217 are at the periphery of respective forming tools 214
and 215. FIG. 11D depicts another embodiment whereby the die platen
is constructed of an electrically conductive component 221 and
electrically insulating component 222, which is made of electrical
and RF energy insulative material. Forming tools 219 and 218 are
electrically conductive, but forming tool 218 further contains
second electrically insulating component 220 around the surface of
upper forming tool 218 which contact tablet shape 206. This
configuration creates an electric field and associated zones of
heating that is preferential to the conductive portions of the die
platen.
[0120] FIG. 12A is similar to FIG. 11D except the die platen 233 in
this embodiment is constructed entirely of electrically conductive
material. FIGS. 12B and 12C depict two embodiments where the die
platen comprises a respective center portion 245 and 254 that are
electrically conductive and respective outer portions 244/246 and
252/253 is are made of electrical and RF energy insulative
material. FIG. 12B further includes insulating component 220 around
the surface of lower forming tool 219. FIG. 12D is a further
embodiment where the forming tools 263 and 262 are made of
electrical and RF energy insulative material. The die platen
portions 264 and 265 are made of electrical and RF energy
insulative material, but there are two respective electrically
conductive portions 267 and 266 which are attached to the RF
generator circuit 200. In this configuration, the electric field is
applied in the horizontal direction across the tablet shape
206.
[0121] As described above, the distance between conductive portions
of the forming tool has a strong effect on field strength and
heating effect. To create a tablet with uniform heating and
texture, a forming tool that is constructed with equidistant
spacing is desirable. FIGS. 13A and 13B depict such a
configuration. In this embodiment, a wave-shaped forming tools 270
and 273 are shown to create a tablet 272 within die platen 271 with
a unique appearance. The profiles of the forming tool surfaces are
equidistant as shown by dimension "X".
[0122] FIG. 14A is an embodiment wherein a non-uniform heating is
used to manufacture tablet 282. In this embodiment, a tablet with
hard and soft zones is created. The forming tools 280 and 281 are
made with protrusions at the surface that create high field
strength (resulting in greater heating) where they are closest
together (shown by the dimension "Z") and weaker field strength
(resulting in lesser heating) where they are further apart (shown
by the dimension "Y").
[0123] In one embodiment, to help reduce sticking, the tablet is
cooled within the forming cavity to cool and/or solidify the
binder. The cooling can be passive cooling (e.g., at room
temperature) or active cooling (e.g., coolant recirculation
cooling). When coolant recirculation cooling is used, the coolant
can optionally circulate through channels inside the forming tools
(e.g., punches or punch platen) and/or die or die platen (e.g., as
discussed above in FIGS. 6A and 6B). In one embodiment, the process
uses a die platen having multiple die cavities and upper and lower
punch platens having multiple upper and lower punched for
simultaneous forming of a plurality of tablets wherein the platens
are actively cooled.
[0124] In one embodiment, there is a single powder blend forming
the tablet shape which is then heated with the RF energy. In
another embodiment, the tablet is formed of at least two different
powder blends, at least one powder blend being RF-curable and at
least one formulation being not RF-curable. When cured with RF
energy, such tablet shape develops two or more dissimilarly cured
zones. In one embodiment, the outside area of the tablet shape is
cured, while the middle of the tablet shape is not cured. By
adjusting the focus of the RF heating and shape of the RF
electrodes, the heat delivered to the tablet shape can be focused
to create customized softer or harder areas on the finished
tablet.
[0125] In one embodiment the RF energy is combined with a second
source of heat including but not limited to infrared, induction, or
convection heating. In one embodiment, the addition of the second
source of heat is particularly useful with a secondary
non-RF-meltable binder present in the powder blend.
[0126] In one embodiment, the level of energy applied to the tablet
is controlled by monitoring and controlling the frequency of the
application of the RF energy. In one embodiment, the powder blend
is sealed within a chamber during the step with which the energy is
applied, so that the water is contained and can be distributed
throughout the powder blend. In one version of this embodiment, the
sealed chamber consists of a die, and at least one heat source
(e.g., RF applying electrode). In one embodiment, upon opening of
the sealed chamber, the fused tablet is further dried in order to
allow for the water to escape. This drying step may be achieved
using the energy source or another source of heat.
[0127] In one embodiment, microwave energy is used (e.g., in place
of radiofrequency energy) to manufacture the tablet. Microwave
heating generally refers to heating with electromagnetic field at
frequencies from about 100 MHz to about 300 GHz. In one embodiment
of the present invention, the RF-energy is within the range of
frequencies from about 500 MHz to about 100 GHz (e.g., from about 1
GHz to 50 GHz, such as from about 1 GHz to about 10 GHz). The
microwave energy is used to heat the binder (e.g., either directly
when the meltable binder is susceptible to microwave energy
("microwave meltable binder") or indirectly when the meltable
binder is not a microwave meltable binder but is heated by a
microwave heatable ingredient within the powder blend. In such an
embodiment, a microwave energy source and microwave electrodes are
used in the machine used to manufacture the dosage form.
Inserts within Tablet Shape
[0128] In one embodiment, an insert is incorporated into the tablet
shape before the energy is delivered. Examples include solid
compressed forms or beads filled with a liquid composition. Such
incorporation of an insert is depicted in FIGS. 3A-3G.
[0129] In one embodiment the pharmaceutically active agent is in
the form of a gel bead, which is liquid filled or semi-solid
filled. The gel bead(s) are added as a portion of the powder blend.
In one embodiment, the tablet of this invention has the added
advantage of not using a strong compaction step, allowing for the
use of liquid or semisolid filled particles or beads which are
deformable since they will not rupture following the reduced
pressure compaction step. These bead walls may contain gelling
substances such as: gelatin; gellan gum; xanthan gum; agar; locust
bean gum; carrageenan; polymers or polysaccharides such as but not
limited to sodium alginate, calcium alginate, hypromellose,
hydroxypropyl cellulose and pullulan; polyethylene oxide; and
starches. The bead walls may further contain a plasticizer such as
glycerin, polyethylene glycol, propylene glycol, triacetin,
triethyl citrate and tributyl citrate. The pharmaceutically active
agent may be dissolved, suspended or dispersed in a filler material
such as but not limited to high fructose corn syrup, sugars,
glycerin, polyethylene glycol, propylene glycol, or oils such as
but not limited to vegetable oil, olive oil, or mineral oil.
[0130] In one embodiment, the insert is substantially free of
RF-absorbing ingredients, in which case application of the RF
energy results in no significant heating of the insert itself. In
other embodiments, the insert contains ingredients and are heated
upon exposure to RF energy and, thus, such inserts can be used to
soften or melt the meltable binder.
Multi-Layer Tablet
[0131] In certain embodiments, the tablet includes at least two
layers, e.g., with different types and/or concentrations of binders
and/or other ingredients or different concentrations of
pharmaceutically active agents. Such an embodiment is shown in
FIGS. 2A-2D. In one embodiment, the tablet includes two layers, one
layer having orally disintegrating properties and another layer
being chewable or swallowable. In one embodiment, one layer has a
meltable binder and another layer does not have a meltable binder.
In one embodiment one layer is compacted at higher compaction force
versus the other layer. In one embodiment, both layers contain same
amount of binder, but have different amount of pharmaceutically
active agents and/or other excipients. In one embodiment, all
properties of the two layers are identical but the colors and/or
flavors of the two layers are different. In one embodiment, one
layer disintegrates faster (e.g., at least two time faster) then
the other layer. In one embodiment, the tablet contains three
layers, wherein the composition of the third layer is different
from the composition of the first layer and the second layer.
[0132] In one embodiment, the tablet comprises two layers, wherein
both the first layer and the second layer include a
pharmaceutically active agent. In one embodiment, the first layer
and the second layer comprise different pharmaceutically active
agents. In one embodiment, they contain the same pharmaceutically
active agent, but in one layer, the pharmaceutically active agent
is released in a modified manner.
[0133] Such multilayer tablets can be made by various means. In one
embodiment, the process includes the steps of (i) adding a first
powder blend to a die platen, wherein the first powder blend
includes a pharmaceutically active agent and a binder; (ii) adding
a second powder blend to the die platen, wherein the second powder
blend includes a binder and wherein the composition of the second
powder blend is different from the composition of the first powder
blend; (iii) compacting a first powder blend and a second powder
blend in the die platen to form a tablet shape; and (iv) applying
energy to the tablet shape for a sufficient period of time to
activate the binders within the tablet shape to fuse the tablet
shape into the tablet. In one embodiment, first powder blend
includes particles containing the pharmaceutically active agent
wherein the particles are coated with the binder. In on embodiment,
the process includes compacting said the previously added powder
blend prior to adding the next powder blend to the die platen.
Effervescent Couple
[0134] In one embodiment, the powder blend further contains one or
more effervescent couples. In one embodiment, effervescent couple
contains one member from the group consisting of sodium
bicarbonate, potassium bicarbonate, calcium carbonate, magnesium
carbonate, and sodium carbonate, and one member selected from the
group consisting of citric acid, malic acid, fumaric acid, tartaric
acid, phosphoric acid, and alginic acid.
[0135] In one embodiment, the combined amount of the effervescent
couple(s) in the powder blend/tablet is from about 2 to about 20
percent by weight, such as from about 2 to about 10 percent by
weight of the total weight of the powder blend/tablet.
Orally Disintegrating Tablet
[0136] In one embodiment, the tablet is designed to disintegrate in
the mouth when placed on the tongue in less than about 60 seconds,
e.g. less than about 45 seconds, e.g. less than about 30 seconds,
e.g. less than about 15 seconds.
[0137] In one embodiment, the tablet meets the criteria for Orally
Disintegrating Tablets (ODTs) as defined by the draft Food and Drug
Administration guidance, as published in April, 2007. In one
embodiment, the tablet meets a two-fold definition for orally
disintegrating tablets including the following criteria: 1) that
the solid tablet is one which contains medicinal substances and
which disintegrates rapidly, usually within a matter of seconds,
when placed upon the tongue and 2) be considered a solid oral
preparation that disintegrates rapidly in the oral cavity, with an
in vitro disintegration time of approximately 30 seconds or less,
when based on the United States Pharmacopeia (USP) disintegration
test method for the specific medicinal substance or substances.
Additional Edible Portion
[0138] In one embodiment, the tablet is contained next to another
edible form. In one embodiment, this edible form is a hard candy or
compressed ring that holds the powder blend during compaction
and/or the RF heating step.
[0139] In one embodiment, the outer hard candy form may be made
using uniplast rolling or roping and subsequent cutting and
stamping, as well as depositing into molds. The hard candy portion
contains one or more sugars selected from the group consisting of
isomalt, sucrose, dextrose, corn syrup, lactitol, and lycasin. In
one embodiment, the hard candy portion contains at least 50% (such
as at least 75%, such as at least 90%) by weight of such
sugar(s).
[0140] In one embodiment, the outer edible form contains a
pharmaceutically active agent and the inner tablet contains a
second portion of the same pharmaceutically active agent that is in
the outer edible form. In one embodiment, the outer edible form
contains a pharmaceutically active agent and the inner tablet
contains a different pharmaceutically active agent than that in the
outer edible form. In one embodiment, the outer edible form
disintegrates at a rate of at least 10 times, such as at least 20
times, the rate of the inner tablet. The first and second portions
can be the same or different.
[0141] In one embodiment, the tablet having an outer edible form
and an inner tablet is coated with an immediate release sugar
coating or film coating. In one embodiment, to produce such a
tablet, the step following the fusing (heating) and subsequent
cooling of the tablet would involve further sugar or film coating
in a coating pan.
Hardness/Density of Tablet Shape/Tablet
[0142] In one embodiment, the tablet is prepared such that the
tablet is relatively soft (e.g., capable of disintegrating in the
mouth or being chewed). In one embodiment, the hardness of the
tablet is preferably less than about 3 kiloponds per square
centimeter (kp/cm.sup.2) (e.g., less than about 2 kp/cm.sup.2, such
as less than about 1 kp/cm.sup.2).
[0143] Hardness is a term used in the art to describe the diametral
breaking strength as measured by conventional pharmaceutical
hardness testing equipment, such as a Schleuniger Hardness Tester.
In order to compare values across different size tablets, the
breaking strength must be normalized for the area of the break.
This normalized value, expressed in kp/cm.sup.2, is sometimes
referred in the art as tablet tensile strength. A general
discussion of tablet hardness testing is found in Leiberman et al.,
Pharmaceutical Dosage Forms--Tablets, Volume 2, 2.sup.nd ed.,
Marcel Dekker Inc., 1990, pp. 213-217, 327-329.
[0144] A more preferred test for hardness of the tablet of the
present invention relies upon a Texture Analyzer TA-XT2i that is
fitted with a 7 millimeter diameter flat faced probe and setup to
measure and report compression force in grams. The probe moves at
0.05 millimeters per second to a depth of penetration of 2
millimeters. The maximum compression force is recorded. In one
embodiment, the measured forces recorded for tablets made in
accordance with the present invention are less than 10,000 grams
(e.g., less than about 1000 grams, such as less than about 700
grams. In one embodiment, the measured forces recorded for tablets
made in accordance with the present invention ranges from about 100
grams to about 6000 grams, such as from about 100 grams to about
1000 grams, such as from about 75 grams to about 700 grams) with a
deviation of .+-.50 grams. In another embodiment the measured
forces recorded for tablets is less than 700 grams.
[0145] In one embodiment, the density of the tablet is less than
about 2 g/cc (e.g., less than about 0.9 g/cc, such as less than
about 0.8 g/cc, such as less than about 0.7 g/cc). In one
embodiment, the difference in the density of the powdered material
following the compaction step is less than about 40 percent (e.g.,
less than about 25 percent, such as less than about 15
percent).
[0146] In one embodiment the tablet is a multilayer tablet. In one
version of this embodiment, wherein the tablet is a bilayer tablet,
the density of one layer is at least 25% greater than the density
of the other layer. In another embodiment, wherein the tablet is a
bilayer tablet, the density of each individual layer less than 2
g/cc (e.g., less than about 0.9 g/cc, such as less than about 0.8
g/cc, such as less than about 0.7 g/cc). In another version of this
embodiment, wherein the tablet is a bilayer tablet, the density of
the entire tablet less than 2 g/cc (e.g., less than about 0.9 g/cc,
such as less than about 0.8 g/cc, such as less than about 0.7
g/cc).
Tablets Coatings
[0147] In one embodiment, the tablet includes an additional outer
coating (e.g., a translucent coating such as a clear coating) to
help limit the friability of the tablet. Suitable materials for
translucent coatings include, but are not limited to, hypromellose,
hydroxypropylcellulose, starch, polyvinyl alcohol, polyethylene
glycol, polyvinylalcohol and polyethylene glycol mixtures and
copolymers, and mixtures thereof. Tablets of the present invention
may include a coating from about 0.05 to about 10 percent, or about
0.1 to about 3 percent by weight of the total tablet.
Surface Treating of the Tablet
[0148] In one embodiment, the surface of the tablet shape and/or
the tablet is further treated with energy (e.g., convection,
infrared, or RF energy) to soften or melt the material on the
surface of the tablet and then cooled or allowed to cool to further
smooth the texture, enhance the gloss of surface of the tablet,
limit the friability of the tablet, and/or provide a mark for
identification. In one embodiment, the surface of the tablet is
further exposed to infrared energy wherein the majority (at least
50 percent, such as least 90 percent, such as at least 99 percent)
of the wavelength of such infrared energy is from about 0.5 to
about 5 micrometers such as from about 0.8 to about 3.5 micrometers
(e.g., by use of a wavelength filter). In one embodiment, the
infrared energy source is a quartz lamp with a parabolic reflector
(e.g., to intensify the energy) and a filter to remove unwanted
frequencies. Examples of such infrared energy sources include the
SPOT IR 4150 (commercially available from Research, Inc., Eden
Prairie, Minn.).
Use of Tablet
[0149] The tablets may be used as swallowable, chewable, or orally
disintegrating tablets to administer the pharmaceutically active
agent.
[0150] In one embodiment, the present invention features a method
of treating an ailment, the method including orally administering
the above-described tablet wherein the tablet includes an amount of
the pharmaceutically active agent effective to treat the ailment.
Examples of such ailments include, but are not limited to, pain
(such as headaches, migraines, sore throat, cramps, back aches and
muscle aches), fever, inflammation, upper respiratory disorders
(such as cough and congestion), infections (such as bacterial and
viral infections), depression, diabetes, obesity, cardiovascular
disorders (such as high cholesterol, triglycerides, and blood
pressure), gastrointestinal disorders (such as nausea, diarrhea,
irritable bowel syndrome and gas), sleep disorders, osteoporosis,
and nicotine dependence.
[0151] In one embodiment, the method is for the treatment of an
upper respiratory disorder, wherein the pharmaceutically active
agent is selected from the group of phenylephrine, cetirizine,
loratadine, fexofenadine, diphenhydramine, dextromethorphan,
chlorpheniramine, chlophedianol, and pseudoephedrine.
[0152] In this embodiment, the "unit dose" is typically accompanied
by dosing directions, which instruct the patient to take an amount
of the pharmaceutically active agent that may be a multiple of the
unit dose depending on, e.g., the age or weight of the patient.
Typically the unit dose volume will contain an amount of
pharmaceutically active agent that is therapeutically effective for
the smallest patient. For example, suitable unit dose volumes may
include one tablet.
EXAMPLES
[0153] Specific embodiments of the present invention are
illustrated by way of the following examples. This invention is not
confined to the specific limitations set forth in these
examples.
Example 1
Manufacture of Powder Blend Containing Loratadine
[0154] The loratadine powder blend for an orally disintegrating
tablet, containing the ingredients of Table 1, is manufactured as
follows:
TABLE-US-00001 TABLE 1 Loratadine Powder Blend Formulation
Ingredient G/Batch Mg/Tablet Dextrose Monohydrate 45.18 120.0
Loratadine 3.765 10.0 Polyethylene Glycol 4000.sup.1 24.475 65.0
Maltodextrin.sup.2 15.062 40.0 Red Colorant 0.028 0.075 Simethicone
DC100.sup.3 5.648 15.0 Sucralose USP 1.13 3.0 Polyethylene Oxide
1.883 5.0 Mint Flavor 2.824 7.5 Total 100 265.575
.sup.1Commercially available from Clariant PF in Rothausstr,
Switzerland .sup.2Commercially available from National Starch in
Bridgewater, NJ .sup.3Commercially available from SPI Pharma in
Wilmington, DE
[0155] First, the sucralose, colorant, and flavor were placed
together into a 500 cc sealable plastic bottle. The mixture was
then blended end-over-end manually for approximately 2 minutes. The
resulting mixture, the dextrose monohydrate, loratadine, and the
polyethylene oxide were then added to another 500 cc sealable
plastic bottle and mixed end-over-end manually for approximately 5
minutes. The resulting mixture was then added to a planetary bowl
mixer, and the simethicone DC100 was added and mixed for
approximately 3 minutes. Lastly, the polyethylene glycol 4000 and
the maltodextrin were added to the mixture and mixed for
approximately 3 minutes.
Example 2
Manufacture of Orally Disintegrating Tablet Containing
Loratadine
[0156] A portion of the powder blend from Example 1 was placed into
a 1/2 inch diameter forming cavity of an electrically insulative
Teflon die platen. The powder blend was then tamped between an
upper and lower flat-faced metal forming tools into a shape
conformal to the surface of the forming tools. The tamping pressure
was typically between 10 and approximately 50 psi of pressure. The
forming tools, die platen and tablet shape were then placed between
the upper RF electrode and lower RF electrode powered by an RF
heating unit using a COSMOS Model C10X16G4 (Cosmos Electronic
Machine Corporation, Farmingdale, N.Y.) RF generator having an
output of 4 KW of power, frequency of 27 MHz, and the vacuum
capacitor is set at 140. The forming tools are heated with
reciculating water at a temperature of 57.degree. C. The upper RF
electrode was brought into contact with the upper forming tool and
the lower RF electrode is brought into contact with lower forming
tool. The RF heating unit was energized for 2 to 5 seconds. The
resulting tablet was then ejected from the die platen using the
lower forming tool.
Example 3
Manufacture of Orally Disintegrating Tablet Containing
Diphenhydramine
[0157] The diphenhydramine powder blend for an orally
disintegrating tablet, containing the ingredients of Table 2, was
manufactured as follows. The sucralose, yellow colorant, flavors,
polyethylene glycol and maltodextrin from the formula in Table 2
were passed through a 20 mesh screen. The sieved materials were
placed into a 500 cc plastic bottle and blended end over end with
the remaining materials in Table 2. The powder blend was placed
into the forming cavity, tamped, and activated with RF energy as
described in Example 2 for approximately 2 to 5 seconds to form the
orally disintegrating tablet and subsequently removed from the die
platen.
TABLE-US-00002 TABLE 2 Powder Blend Formulation Containing
Diphenhydramine (DPH) Ingredient G/Batch Mg/Tablet Dextrose
Monohydrate 304.11 219.0 Diphenhydramine (Coated).sup.3 49.57 35.70
Polyethylene Glycol 8000.sup.1 44.16 31.80 Maltodextrin.sup.2 88.46
63.70 Yellow Colorant 0.78 0.56 Orange Flavor 1.65 1.19 Vanilla
Flavor 2.21 1.59 Sucralose USP 1.11 0.80 Citric Acid USP Anhydrous
7.96 5.73 Total 500.00 360.07 .sup.1Commercially available from
Clariant PF in Rothausstr, Switzerland .sup.2Commercially available
from National Starch in Bridgewater, NJ .sup.3Encapsulated
Diphenhydramine coated utilizing cellulose acetate and
polymethacrylate, utilizing process outlined in U.S. Pat. No.
5,997,905 incorporated herein by reference
Example 4
Manufacture of Orally Disintegrating Tablet Placebo Containing
Dextrose Monohydrate
[0158] The placebo powder blend for an orally disintegrating
tablet, containing the ingredients of Table 3, was manufactured as
follows. The sucralose, yellow colorant, flavors, polyethylene
glycol and maltodextrin from the formula in Table 3 were passed
through a 20 mesh screen. The sieved materials were placed into a
500 cc plastic bottle and blended end over end with the remaining
materials in Table 3. The powder blend was placed into the forming
cavity, tamped, and activated with RF energy as described in
Example 2 for approximately 2 to 5 seconds to form the orally
disintegrating tablet and subsequently removed from the die
platen.
TABLE-US-00003 TABLE 3 Powder Blend Formulation Ingredient G/Batch
Mg/Tablet Dextrose Monohydrate 283.04 255.0 Polyethylene Glycol
8000.sup.1 35.30 31.80 Maltodextrin.sup.2 70.71 63.70 Yellow
Colorant 0.62 0.56 Orange Flavor 1.32 1.19 Vanilla Flavor 1.76 1.59
Sucralose USP 0.89 0.80 Citric Acid Anhydrous USP 6.36 5.73 Total
400.00 360.37 .sup.1Commercially available from Clariant PF in
Rothausstr, Switzerland .sup.3Commercially available from National
Starch in Bridgewater, NJ
Example 5
Manufacture of Orally Disintegrating Tablet Placebo Containing
Erythritol
[0159] The placebo powder blend for an orally disintegrating
tablet, containing the ingredients of Table 4, was manufactured as
follows. The sucralose, yellow colorant, flavors, polyethylene
glycol and maltodextrin from the formula in Table 4 were passed
through a 20 mesh screen. The sieved materials were placed into a
500 cc plastic bottle and blended end over end with the remaining
materials in Table 4. The powder blend was placed into the forming
cavity, tamped, and activated with RF energy as described in
Example 2 for approximately 2 to 5 seconds to form the orally
disintegrating tablet and subsequently removed from the die
platen.
TABLE-US-00004 TABLE 4 Placebo Powder Blend Formulation Containing
Erythritol Ingredient G/Batch Mg/Tablet Erythritol Directly 212.28
255.0 Compressible.sup.3 Polyethylene Glycol 8000.sup.1 26.47 31.80
Maltodextrin.sup.2 53.03 63.70 Yellow Colorant 0.47 0.56 Orange
Flavor 0.99 1.19 Vanilla Flavor 1.32 1.59 Sucralose USP 0.67 0.80
Citric Acid Anhydrous USP 4.77 5.73 Total 300.00 360.37
.sup.1Commercially available from Clariant PF in Rothausstr,
Switzerland .sup.3Commercially available from National Starch in
Bridgewater, NJ .sup.4Commercially available from Corn Products in
Westchester, IL
Example 6
Manufacture of a Comparative Compressed Chewable Placebo Tablet
[0160] The placebo powder blend for a comparative chewable placebo
tablet, containing the ingredients of Table 5, was manufactured as
follows. The sucralose, yellow color, and flavors were passed
through a 20 mesh screen prior to blending. The sieved materials
were blended with the remaining materials in the formula in Table 5
and added to a 500 cc plastic bottle and blended end over end for
approximately 3 minutes and discharged. The tablets were compressed
using two different compression forces as follows: Tablets (a) were
compressed on a single station manual Carver press (commercially
available from Carver Press Corporation in Wabash, Ind.) at 0.7
Metric tons (6.86 KiloNewtons) and Tablets (b) were compressed at
0.25 Metric tons (2.45 KiloNewtons). Tablets (b) were extremely
friable and fragile given the low amount of pressure applied to the
formulation.
TABLE-US-00005 TABLE 5 Placebo Powder Blend Formulation for
Compressed Tablet Ingredient G/Batch Mg/Tablet Dextrose Monohydrate
114.773 138.00 Polyethylene Glycol 4000.sup.1 41.584 50.00
Maltodextrin.sup.2 35.763 43.00 Blue Colorant 0.075 0.0907 Yellow
Colorant 0.153 0.1842 Vanilla Flavor 1.830 2.20 Sucralose USP 1.248
1.50 Mint Flavor.sup.1 4.574 5.50 Total 200 240.47
.sup.1Commercially available from Clariant PF in Rothausstr,
Switzerland .sup.3Commercially available from National Starch in
Bridgewater, NJ
Example 7
Manufacture of a Comparative Compressed Chewable Containing
Acetaminophen
[0161] The placebo powder blend for a chewable tablet, containing
the ingredients of Table 6, was manufactured as follows. The
sucralose, yellow color, flavors, and citric acid were passed
through a 20 mesh screen prior to blending. The sieved materials
were blended with the remaining materials in the formula in Table 6
and added to a 500 cc plastic bottle and blended end over end for
approximately 3 minutes and discharged. The tablets were compressed
using two different compression forces as follows: Tablets (a) were
lightly compressed on a single station manual Carver press at 0.7
Metric tons (6.86 KiloNewtons) and Tablets (b) were compressed at
0.25 Metric tons (2.45 KiloNewtons). Tablets (b) were extremely
friable and fragile given the low amount of pressure applied to the
formulation.
TABLE-US-00006 TABLE 6 Powder Blend Formulation Containing
Acetaminophen Ingredient G/Batch Mg/Tablet Dextrose Monohydrate
32.284 94.00 Acetaminophen (Coated).sup.3 29.989 87.32 Polyethylene
Glycol 4000.sup.1 5.152 15.00 Maltodextrin.sup.2 20.607 60.00
Yellow Colorant 0.120 0.35 Orange Flavor 0.343 1.00 Vanilla Flavor
0.515 1.50 Sucralose USP 0.343 1.00 Crosslinked Povidone.sup.5
2.061 6.00 Polyethylene Oxide (Grade 6.869 20.00 WSR 303).sup.4
Citric Acid USP Anhydrous 1.717 5.00 Total 100 291.17
.sup.1Commercially available from Clariant PF in Rothausstr,
Switzerland .sup.2Commercially available from National Starch in
Bridgewater, NJ .sup.3Encapsulated Acetaminophen coated utilizing
cellulose acetate and povidone, utilizing process outlined in U.S.
Pat. No. 4,851,226 incorporated herein by reference
.sup.4Commercially available from the DOW Corporation in Midland,
MI .sup.5Commercially available as Kollidon CL-M from the BASF
Corporation in Florham Park, NJ
Example 8
Density Measurements of ODT and Compressed Tablets
[0162] Three tablets from each of Examples 3, 4, 5, 6, and 7 and a
comparative orally disintegrative tablet (Alavert.RTM. Loratidine
Orally Disintegrating Tablet, Wyeth Consumer Healthcare, Madison,
N.J., USA) were measured to determine the density of compressed
tablets and tablets produced utilizing the method of the present
invention. The density was calculated utilizing the volume of a
cylinder as calculated using the width and thickness of the tablet
divided by the weight of individual tablets.
TABLE-US-00007 TABLE 8 Tablet Density Measurements Weight Diameter
Height Volume Density Example (mg) (mm) (mm) (mm.sup.3)
(mg/mm.sup.3) Example 3 (1) 379 13.13 5.00 677.0 0.560 Example 3
(2) 403 13.10 4.97 669.9 0.602 Example 3 (3) 409 13.03 4.87 649.4
0.630 Example 4 (1) 347 12.90 4.85 633.9 0.547 Example 4 (2) 416
12.97 4.96 655.3 0.635 Example 4 (3) 398 13.06 4.95 663.1 0.600
Example 5 (1) 419 12.90 5.38 703.2 0.596 Example 5 (2) 397 13.15
5.32 722.5 0.549 Example 5 (3) 352 12.87 5.00 650.5 0.541 Example
6a (1) 399 11.18 3.32 325.9 1.220 Example 6a (2) 372 11.16 3.06
299.3 1.240 Example 6a (3) 391 11.18 3.25 319.0 1.230 Example 6b
(1) 433 11.20 4.27 420.7 1.030 Example 6b (2) 442 11.22 4.35 430.1
1.030 Example 6b (3) 404 11.18 3.93 385.8 1.050 Example 7a (1) 364
11.20 3.26 321.2 1.130 Example 7a (2) 328 11.18 2.94 288.6 1.140
Example 7a (3) 404 11.17 3.65 357.7 1.130 Example 7b (1) 413 11.25
4.66 463.2 0.890 Example 7b (2) 451 11.21 5.00 493.5 0.910 Example
7b (3) 437 11.22 4.82 476.6 0.920 Alavert .RTM..sup.1 Tablet 1
305.67 9.68 3.67 270.0 1.13* Alavert .RTM..sup.1 Tablet 2 296.50
9.71 3.65 270.0 1.10* Alavert .RTM..sup.1 Tablet 3 294.81 9.71 3.63
269.0 1.10* *The Alavert tablets have beveled edges which slightly
lowered the volume. Therefore, Alavert .RTM. Loratidine Orally
Disintegrating Tablets were also measured for density using a
volume displacement method, wherein the tablets were placed into a
volume of mineral oil. The density for 3 tablets of Alavert were
measured at 1.6, 1.2, and 1.5 mg/mm.sup.3 using this method.
As is shown in table 8, the ODT tablets of the present invention
(Examples 3, 4, and 5) has densities ranging from 0.541-0.635
mg/mm.sup.3, which were much lower than the comparative chewable
tablets of Examples 6 and 7 (having densities ranging from 0.890
1.240 mg/mm.sup.3) and the Alavert.RTM. orally disintegrating
tablets (having densities ranging from 1.10-1.6 mg/mm.sup.3). Thus,
the ODT tablets of the present invention, thus, had densities
approximately half of that of the comparative examples.
Example 9
Disintegration Test Utilizing Texture Analyzer TA XT Plus
[0163] The following test was performed utilizing the Texture
Analyzer TA XT Plus, commercially available from Texture
Technologies in Scarsdale, N.Y. The texture Analyzer was equipped
with a TA-55 probe, and set to a probe speed of 0.1 mm/sec. The
individual tablet was placed into a 5 mm graduated cylinder, and
placed onto the short axis. 20 grams of force was applied to the
tablet via the 5 mm probe. The force was applied and at approx. 10
mL of de-ionized water at 25.degree. C. was added to cover the
tablet. The force was analyzed over time and the following tablets
were analyzed: the tablets of Example 6a and the tablets of Example
3. The tablets of the present invention (Example 3) disintegrated
immediately following the addition of the water as indicated by the
probe distance, which increased from 0 mm to greater than 1 mm
between 10 and 20 seconds. The tablets from Example 6a, which were
representative of chewable tablets, disintegrated in 84.30 seconds
from the addition of water as measured by the change in slope in
the texture analyzer, where tablets of Example 3 were completely
disintegrated in 6.99 seconds from the addition of water.
Example 10
Preparation of Tablet Cores and Sintered Tablet Containing
Acetaminophen
[0164] The tablet cores of Table 9 are prepared as follows. Equal
parts of sucralose, tartaric acid, strawberry flavor, maltodextrin
and Sorbidex P powdered sobirtol are manually passed through a 50
mesh screen. The loratidine, flavor blend, Sorbidex P and Tapioca
Maltodextrin are added to the above mixture in a plastic bottle,
mixed end-over end for approximately three minutes, and then
discharged. The blend is then individually dosed into a tablet die
utilizing 624 mg of the blend per tablet
[0165] A portion of the powder blend from Example 1 is placed into
an electrically insulative Teflon, or ceramic die block,
approximately 1.1'' in diameter and 0.175'' thick. The powder blend
is then tamped between an upper and lower metal forming tools into
a shape conformal to the surface of the forming tools. The tamping
pressure is typically between 10 and approximately 100 psi of
pressure. The forming tools, die block and tablet shape are then
placed between the upper electrode and lower electrode of an RF
heating unit The upper electrode is brought into contact with the
upper forming tool and the lower electrode is brought into contact
with lower forming tool. The RF heating unit is energized for 2
seconds. After cooling, the resulting tablet dosage form is then
ejected from the die block using the lower forming tool.
TABLE-US-00008 TABLE 9 Loratidine 10 mg Dosage Form Core
Formulation Material G/Batch mg/tab Weight % Dextrose Monohydrate,
Fine powder 33.86 118.51 33.86 Flavor Blend.sup.2 5.88 20.58 5.88
Sorbidex P.sup.1 (Sorbitol powder) 33.86 118.51 33.86 Loratidine
2.86 10.0 2.86 Tapioca Maltodextrin (N-Zorbit M.sup.3) 23.53 82.36
23.53 TOTAL 100.0 350.0 100.0 .sup.1Commercially available from
Cargill Corporation in Wayzata, Minnesota .sup.2Contains equal
parts of Strawberry Cream Flavor, Sucralose, Tartaric Acid,
Maltodextrin, Sorbidex P (Sorbitol powder) .sup.3Commercially
available from National Starch in Bridgewater, NJ
Example 11
Preparation of Bi-Layer Orally Disintegrating Tablet
[0166] A bi-layered orally disintegrating tablet having loratadine
in one layer and diphenhydramine in the other layer is manufactured
as follows. 265.58 mg of the powder blend containing loratadine
from Table 1 is placed into the forming cavity and tamped. 360.073
mg of the powder blend containing diphenhydramine from Table 2 is
then added into the forming cavity and tamped to create a 625.65 mg
tablet. The cavity is then activated with RF energy as described in
Example 2 for approximately 2 to 5 seconds to form the orally
disintegrating tablet and subsequently removed from the die
platen.
Example 12
Preparation of Bi-Layer Placebo Orally Disintegrating Tablet
(ODT)
[0167] A bi-layered orally disintegrating placebo tablet having
colorant in one layer and no colorant in the other layer is
manufactured as follows. 90.0 mg of the powder blend containing
colorant from Table 10 is placed into the forming cavity and
lightly tamped. 90.0 mg of the powder blend without colorant from
Table 11 is then added into the forming cavity and tamped. The
cavity is then activated with RF energy as described in Example 2
for approximately 2 to 5 seconds to form the orally disintegrating
tablet at 180.0 mg and subsequently removed from the die
platen.
TABLE-US-00009 TABLE 10 Layer 1 of Bilayer Placebo ODT Material
G/Batch mg/tab layer Weight % Dextrose Monohydrate, Fine powder
57.020 51.318 57.020 Sucralose 0.473 0.426 0.473 Peppermint
Flavor.sup.1 2.100 1.890 2.100 Vanilla Flavor.sup.1 0.900 0.810
0.900 Propylene Glycol 4000 20.883 18.795 20.883 Tapioca
Maltodextrin (N-Zorbit M.sup.2) 18.444 16.600 18.444 Blue #1 Al
Lake Colorant 0.060 0.0540 0.060 Yellow #10 Al Lake Colorant 0.120
0.108 0.120 TOTAL 100.0 90.00 100.0 .sup.1Commercially available
from the International Flavors and Fragrances Corporation in
Hazlet, NJ .sup.2Commercially available from National Starch in
Bridgewater, NJ
TABLE-US-00010 TABLE 11 Layer 2 of Bilayer Placebo ODT Material
G/Batch mg/tab layer Weight % Dextrose Monohydrate, Fine powder
57.123 51.411 57.123 Sucralose 0.474 0.427 0.474 Peppermint Flavor
2.100 1.890 2.100 Vanilla Flavor 0.900 0.810 0.900 Propylene Glycol
4000 20.921 18.829 20.921 Tapioca Maltodextrin (N-Zorbit M) 18.482
16.634 18.482 TOTAL 100.0 90.0 100.0
[0168] It is understood that while the invention has been described
in conjunction with the detailed description thereof, that the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the claims.
* * * * *